Shrivastav D, Singh DD. Emerging roles of microRNAs as diagnostics and potential therapeutic interest in type 2 diabetes mellitus. World J Clin Cases 2024; 12(3): 525-537 [PMID: 38322458 DOI: 10.12998/wjcc.v12.i3.525]
Corresponding Author of This Article
Desh Deepak Singh, PhD, Associate Professor, Amity Institute of Biotechnology, Amity University Rajasthan, SP-1, Kant Kalwar, RIICO Industrial Area, NH-11C, Jaipur 303002, Rajasthan, India. ddsbms@gmail.com
Research Domain of This Article
Biochemistry & Molecular Biology
Article-Type of This Article
Systematic Reviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Jan 26, 2024; 12(3): 525-537 Published online Jan 26, 2024. doi: 10.12998/wjcc.v12.i3.525
Emerging roles of microRNAs as diagnostics and potential therapeutic interest in type 2 diabetes mellitus
Dharmsheel Shrivastav, Desh Deepak Singh
Dharmsheel Shrivastav, Desh Deepak Singh, Amity Institute of Biotechnology, Amity University Rajasthan, Jaipur 303002, India
Author contributions: Shrivastav D and Singh DD design and written the manuscript and all data were generated in-house and that no paper mill was used.
Conflict-of-interest statement: All the authors declare that they have no conflict of interest.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Desh Deepak Singh, PhD, Associate Professor, Amity Institute of Biotechnology, Amity University Rajasthan, SP-1, Kant Kalwar, RIICO Industrial Area, NH-11C, Jaipur 303002, Rajasthan, India. ddsbms@gmail.com
Received: November 7, 2023 Peer-review started: November 7, 2023 First decision: December 15, 2023 Revised: December 18, 2023 Accepted: January 3, 2024 Article in press: January 3, 2024 Published online: January 26, 2024 Processing time: 71 Days and 23.4 Hours
ARTICLE HIGHLIGHTS
Research background
Type 2 diabetes mellitus (T2DM) as a metabolic disorder due to impaired glucose utilization. Uncontrolled high sugar levels generate advanced glycation end products (AGEs) via receptor of advanced glycation end products (RAGE) receptor, causing complications. MiRNAs regulate genes linked to diabetes, impacting AGEs pathogenesis and influencing T2DM aspects—risk, diagnostics, complications, and therapeutic potential in managing metabolic pathways, inflammation, oxidative stress, and vascular complications. MiRNAs also hold promise as early diagnostic biomarkers, paving the way for innovative diabetes therapies.
Research motivation
Understanding miRNA roles in T2DM's metabolic pathways and their influence on AGEs/RAGE axis presents therapeutic prospects for managing diabetes complications. Identifying miRNAs as diagnostic markers could revolutionize early intervention strategies. Exploring their impact on gene regulation offers insights for innovative therapeutic targets, potentially mitigating diabetes-related complexities.
Research objectives
To investigate the regulatory role of specific miRNAs in T2DM's metabolic pathways affected by AGEs/RAGE axis, exploring their potential as diagnostic markers and therapeutic targets for managing diabetes complications.
Research methods
The study systematically searched PubMed using specific keywords to identify free, full-length research articles evaluating miRNA involvement in T2DM and its complications. Twelve articles were selected after assessing relevance to genetic and molecular disease mechanisms. The investigation focused on miRNA impact on AGEs/RAGE axis and their associations with T2DM aspects.
Research results
Multiple miRNAs, including miR-96-5p, miR-7-5p, miR-132, has_circ_0071106, miR-143, miR-21, miR-145-5p, exhibit links to diverse facets of T2DM—risk, diagnostics, complications, and gene regulation. These miRNAs are intricately associated with metabolic pathways affected by the AGEs/RAGE axis, illuminating potential roles as diagnostic markers and therapeutic targets for managing T2DM complexities.
Research conclusions
Targeting the AGEs/RAGE axis via miRNA regulation holds promise for managing T2DM complexities. MiRNAs offer therapeutic potential by influencing affected metabolic pathways, potentially mitigating inflammation, oxidative stress, and vascular complications. Moreover, their role as early diagnostic biomarkers suggests innovative strategies for addressing diabetes and its associated complications.
Research perspectives
Further exploration of miRNA-mediated regulation in the context of the AGEs/RAGE axis holds significant promise for advancing T2DM management. Investigating specific miRNAs' functional roles could unveil novel therapeutic avenues, potentially targeting metabolic pathways to alleviate complications. Additionally, validating miRNAs as reliable early diagnostic markers might revolutionize diabetes intervention strategies.
